Medical Developments International Limited (ASX: MVP) - ETF Exposure

- Current share price for MVP : $0.480

Medical Developments International Limited (MVP) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Company engaged in delivering emergency medical solutions. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine and for analgesia during short surgical procedures.

MVP General Information ⁺

ASX Code	MVP
Website	http://www.medicaldev.com
Industry/Sector	Pharmaceuticals
Market Cap ($M)	54
MVP Share Price	$0.480
Day High	$0.495
Day Low	$0.480
Last Close	$0.480
MVP Share Price Movement	- ( No change )

Prices as at 16:40, 12 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to MVP

Medical Developments International Limited (MVP) is held across 1 ETF spanning strategies that include pharmaceuticals exposure . Its weighting in those funds means performance can have an outsized influence - when MVP moves, funds like DACE that hold it can move with it.

For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to MVP , while the average exposure across all 1 ETF that hold it is around 0% .

Top ETF holdings

Dimensional Australian Core Equity (Managed Fund) (DACE) ~ 0%

Last updated: ETF data and holdings as at 12 August 2026

Own MVP directly or through an ETF?

How does holding Medical Developments International Limited (MVP) shares directly compare to ETFs that include it?

	MVP Direct	DACE ASX
Holdings	1 company	470 holdings
MVP Weight	100%	0%
Diversification	Single Stock	Broad
Annual Cost	Brokerage only	0.28% p.a.
Approx. Yield	-	2.93%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not MVP's direct yield. Annual cost uses each ETF's MER.

MVP Exposure on $10,000 investment

How a $10,000 investment in Medical Developments International Limited (MVP) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Medical Developments International Limited (MVP)	Direct share	$0.480	4.35%	+$435	$10,435
Dimensional Australian Core Equity (Managed Fund) (DACE)	Equity - Australia Strategy	$19.470	2.20%	+$220	$10,220

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Medical Developments International Limited (MVP) ETFs

1 ETF hold Medical Developments International Limited (MVP).

ETF	MVP Weight	MER	Yield
Dimensional Australian Core Equity (Managed Fund) (DACE)	0%	0.28%	2.93%

Medical Developments International Limited (MVP) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
Result	2¢	100%	5 Mar 2020	17 Apr 2020	-	-	-
HFResult	2¢	100%	3 Sep 2019	4 Oct 2019	-	-	-
Result	2¢	100%	7 Mar 2019	17 Apr 2019	-	-	-

See all dividends from Medical Developments International Limited (MVP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Medical Developments International Limited (MVP) price-sensitive announcements

MVP - Appendix 4C and Quarterly Activity Report 30 June 2026

Medical Developments International Limited reported a positive free cash flow for Q4 and t

Medical Developments International Limited (MVP)
24 Jul 2026 | 8:24 AM

MVP - Appendix 4C and Quarterly Activity Report 31 March 2026

Medical Developments International (MVP) released its Appendix 4C and Quarterly Activity R

Medical Developments International Limited (MVP)
24 Apr 2026 | 8:58 AM

MVP - FY26 Half Year Announcement

Medical Developments International Limited (MVP) reported its FY26 Half Year results, high

Medical Developments International Limited (MVP)
19 Feb 2026 | 8:55 AM

MVP - FY26 Half Year Presentation

Medical Developments International Limited (MVP) presented its FY26 Half Year Results, emp

Medical Developments International Limited (MVP)
19 Feb 2026 | 8:54 AM

Medical Developments International Limited (MVP) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Medical Developments International Limited (MVP) ORDINARY FULLY PAID	Health Care	$54	FY26 Full Year Results Announcement Details	12 Aug 2026 4:16PM	$0.480	$0.480	fallen by 0%
Medical Developments International Limited (MVP) ORDINARY FULLY PAID	Health Care	$54	Appendix 4C and Quarterly Activity Report 30 June 2026	24 Jul 2026 8:24AM	$0.390	$0.480	risen by 23.08%
Medical Developments International Limited (MVP) ORDINARY FULLY PAID	Health Care	$54	Change in substantial holding	1 Jul 2026 12:07PM	$0.390	$0.480	risen by 23.08%
Medical Developments International Limited (MVP) ORDINARY FULLY PAID	Health Care	$54	Becoming a substantial holder	3 Jun 2026 3:23PM	$0.375	$0.480	risen by 28%
Medical Developments International Limited (MVP) ORDINARY FULLY PAID	Health Care	$54	Change in substantial holding	2 Jun 2026 1:13PM	$0.375	$0.480	risen by 28%
Medical Developments International Limited (MVP) ORDINARY FULLY PAID	Health Care	$54	Notification of cessation of securities - MVP	14 May 2026 1:47PM	$0.435	$0.480	risen by 10.34%

MVP Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	PER	Yield (%)	Franking (%)
2025A	$0.09	$0.10	-100.30%	565.40	0.00%	0.0%
2024A	-$24.62	-$27.80	34.80%	0.00	0.00%	0.0%
2023A	-$17.83	-$20.60	26.10%	0.00	0.00%	0.0%

MVP Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Clarity Pharmaceuticals Ltd (CU6)	$1,067M	0.3002	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Medical Developments International Limited (MVP)	$54M	-1.0032	0.0000	0.0000	533.3333	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,997M	-0.7857	0.2462	0.9655	101.5900	81.5172	41.4737	0.00%	0.00%	0.00%

MVP Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.80	533.30	0.98	0.00
Market	0.31	13.10	1.15	0.66
Sector	0.52	33.10	2.46	2.71

MVP Directors

Name	Position	Start Date
Mr Leon Hoare	Non-Executive Director	27 Sep 2013
Ms Christine Emmanuel-Donnelly	Non-Executive Director	26 May 2020
Mr Paul Townsend	Non-Executive Director	30 May 2025
Dr Russell Basser	Non-Executive Director	31 Aug 2023
Mr Mark Fladrich	Non-Executive Director, Non-Executive Chairman	1 Apr 2025

Medical Developments International Limited (MVP) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
30 Oct 2025	BASSER, Russell	Buy	Direct Shares	40,000	$0.706	$28,227.000
30 Sep 2025	FLADRICH, Mark	Buy	Direct Shares	62,858	$0.710	$44,629.000
22 Sep 2025	TOWNSEND, Paul	Buy	Direct Shares	25,000	$0.671	$16,785.310

See all changes in directors' interest & trades for Medical Developments International Limited (MVP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

MVP Management

Name	Position
Brent MacGregor	Chief Executive Officer
A James	Chief Financial Officer
Tara Eaton	Company Secretary,General Counsel

MVP Calendar of Events

Date	Event
18 February 2027	Report (Interim)
07 September 2026	Report (Annual)
20 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us